Insiders · TCRR

Garry E Menzel

Officer, Director at Tcr2 Therapeutics Inc. (TCRR)

Garry E Menzel has filed 31 insider reports with the SEC since January 2021, as director at Black Diamond Therapeutics, Inc. (BDTX), director at Stoke Therapeutics, Inc. (STOK) and director at Adaptimmune Therapeutics PLC (ADAP) and at 1 more company. Garry E Menzel made no open-market purchases or sales in the last 12 months. The latest filing, on June 29, 2026, reports grant or award at Black Diamond Therapeutics, Inc. (BDTX).

Filings
31
Companies
4
Bought on market
None
Sold on market
$145K

Companies where Garry E Menzel is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Black Diamond Therapeutics, Inc. logo
BDTX
Black Diamond Therapeutics, Inc.
Director$1.31Jun 29, 2026
Stoke Therapeutics, Inc. logo
STOK
Stoke Therapeutics, Inc.
Directorsince August 2020$26.81Jun 5, 2025
Adaptimmune Therapeutics PLC logo
ADAP
Adaptimmune Therapeutics PLC
Directorsince June 202375,056$43.4KJul 1, 2024
Tcr2 Therapeutics Inc. logo
TCRR
Tcr2 Therapeutics Inc.
Officer, Director0$102KJun 1, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Garry E Menzel.

Compare Garry E Menzel with

Other insiders at the same companies

Questions about Garry E Menzel

What is Garry E Menzel's role at Tcr2 Therapeutics Inc.?
Garry E Menzel reports to the SEC as officer and director at Tcr2 Therapeutics Inc. (TCRR), according to the latest filing on June 1, 2023. Garry E Menzel has also filed as director at Black Diamond Therapeutics, Inc. (BDTX), director at Stoke Therapeutics, Inc. (STOK) and director at Adaptimmune Therapeutics PLC (ADAP).
How many shares does Garry E Menzel own?
After the latest filing that states it, Garry E Menzel directly owned 75,056 shares of Adaptimmune Therapeutics PLC (ADAP). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Garry E Menzel bought or sold stock recently?
The most recent open-market sale was on July 10, 2023: sold 47,702 shares of Adaptimmune Therapeutics PLC (ADAP) for $43.4K at an average of $0.91.
How do I get alerts when Garry E Menzel files?
Follow Garry E Menzel on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Garry E Menzel (SEC CIK 0001556064). Totals count each trade once, skipping amendments whose original is on file, from Jan 27, 2021 on. View on SEC EDGAR · Get this as JSON